SG11202002579SA - Preparation and storage of liposomal rna formulations suitable for therapy - Google Patents

Preparation and storage of liposomal rna formulations suitable for therapy

Info

Publication number
SG11202002579SA
SG11202002579SA SG11202002579SA SG11202002579SA SG11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA SG 11202002579S A SG11202002579S A SG 11202002579SA
Authority
SG
Singapore
Prior art keywords
therapy
preparation
storage
formulations suitable
rna formulations
Prior art date
Application number
SG11202002579SA
Inventor
Heinrich Haas
Sebastian Hörner
Borquez Isaac Hernan Esparza
Thomas Michael Hiller
Ferdia Bates
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of SG11202002579SA publication Critical patent/SG11202002579SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
SG11202002579SA 2017-10-20 2018-10-18 Preparation and storage of liposomal rna formulations suitable for therapy SG11202002579SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574965P 2017-10-20 2017-10-20
PCT/EP2018/078587 WO2019077053A1 (en) 2017-10-20 2018-10-18 Preparation and storage of liposomal rna formulations suitable for therapy

Publications (1)

Publication Number Publication Date
SG11202002579SA true SG11202002579SA (en) 2020-05-28

Family

ID=63965663

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002579SA SG11202002579SA (en) 2017-10-20 2018-10-18 Preparation and storage of liposomal rna formulations suitable for therapy

Country Status (16)

Country Link
US (2) US11395799B2 (en)
EP (2) EP3858333A1 (en)
JP (2) JP2021500324A (en)
KR (1) KR20200100619A (en)
CN (3) CN114344486A (en)
AR (2) AR113782A1 (en)
AU (2) AU2018350846B2 (en)
BR (1) BR112020007470A2 (en)
CA (1) CA3078292A1 (en)
IL (1) IL273852A (en)
MX (1) MX2020003413A (en)
RU (1) RU2022103533A (en)
SG (1) SG11202002579SA (en)
TW (2) TW201927288A (en)
WO (1) WO2019077053A1 (en)
ZA (1) ZA202001675B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
FI3589661T3 (en) 2017-03-02 2024-01-31 Genentech Inc Adjuvant treatment of her2-positive breast cancer
CN114344486A (en) 2017-10-20 2022-04-15 生物技术公司 Preparation and storage of liposomal RNA formulations suitable for therapeutic use
US11684577B2 (en) * 2018-01-18 2023-06-27 Etherna Immunotherapies Nv Lipid nanoparticles
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
MX2023002670A (en) 2020-09-08 2023-05-08 Genentech Inc Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners.
TW202228727A (en) * 2020-10-01 2022-08-01 德商拜恩迪克公司 Preparation and storage of liposomal rna formulations suitable for therapy
BR112023016897A2 (en) * 2021-02-23 2023-11-21 Natures Toolbox Inc ENCAPSULATION OF LIPID NANOPARTICLES (LNP) OF MRNA PRODUCTS
EP4334944A1 (en) 2021-05-04 2024-03-13 BioNTech SE Immunogen selection
KR20240042414A (en) 2021-07-29 2024-04-02 비온테크 에스이 Compositions and methods for treating melanoma
WO2023057596A1 (en) 2021-10-06 2023-04-13 Leon-Nanodrugs Gmbh Method for preparing lipid nanoparticles
CN114601747A (en) * 2022-03-07 2022-06-10 广州市万千粉丝化妆品有限公司 Application of nucleoprotein telomerase with functions of promoting growth of protein and RNA, prolonging cell telomere and proliferating in cosmetics
WO2024011033A1 (en) 2022-07-07 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogens and methods for inducing an immune response
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769357B2 (en) * 1999-07-15 2004-01-22 University Of British Columbia, The Methods for preparation of lipid-encapsulated therapeutic agents
DE10109897A1 (en) 2001-02-21 2002-11-07 Novosom Ag Optional cationic liposomes and their use
CA2469491A1 (en) * 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US7008403B1 (en) 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
ATE476964T1 (en) * 2003-06-04 2010-08-15 Univ Georgetown METHOD FOR IMPROVING THE STABILITY AND SHELF LIFE OF LIPOSOME COMPLEXES
EP1512393A1 (en) * 2003-09-08 2005-03-09 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Process for the production of homogeneous liposomes and lipoplexes
US20110165223A1 (en) * 2008-01-02 2011-07-07 The Johns Hopkins University Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
WO2011127255A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Preparation of lipid nanoparticles
EP2675918B1 (en) 2011-02-15 2017-11-08 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
CN102144973A (en) 2011-03-31 2011-08-10 中国药科大学 Prescription composition of optimized siRNA cation liposome
CN102727436A (en) 2011-04-15 2012-10-17 百奥迈科生物技术有限公司 Nucleic acid liposome drug preparation
LT2773326T (en) 2011-11-04 2019-04-25 Nitto Denko Corporation Method for sterilely producing lipid-nucleic acid particles
SI2830593T1 (en) 2012-03-26 2019-07-31 Biontech Rna Pharmaceuticals Gmbh Rna formulation for immunotherapy
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CN103194489B (en) 2013-03-26 2015-09-30 中国科学院过程工程研究所 New Cationic Liposome nucleic acid drug preparation, and its preparation method and application
RU2016109938A (en) * 2013-08-21 2017-09-26 Куревак Аг COMPOSITION AND VACCINE FOR TREATMENT OF PROSTATE CANCER
EP3049065A1 (en) * 2013-09-26 2016-08-03 BioNTech AG Particles comprising a shell with rna
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
CN107533076A (en) * 2015-02-24 2018-01-02 不列颠哥伦比亚大学 Continuous stream microfluid system
CN107427791B (en) * 2015-03-19 2021-05-14 康涅狄格大学 System and method for continuous manufacture of liposomal pharmaceutical formulations
WO2016155809A1 (en) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
CN114344486A (en) 2017-10-20 2022-04-15 生物技术公司 Preparation and storage of liposomal RNA formulations suitable for therapeutic use

Also Published As

Publication number Publication date
CN114344486A (en) 2022-04-15
CN114392233A (en) 2022-04-26
RU2022103533A (en) 2022-03-10
AU2018350846B2 (en) 2022-12-08
RU2020113577A3 (en) 2022-02-16
US11395799B2 (en) 2022-07-26
AR113782A1 (en) 2020-06-10
AR127361A2 (en) 2024-01-17
WO2019077053A1 (en) 2019-04-25
AU2023201185A1 (en) 2023-04-06
EP3697384A1 (en) 2020-08-26
RU2020113577A (en) 2021-11-22
JP2023052184A (en) 2023-04-11
KR20200100619A (en) 2020-08-26
CA3078292A1 (en) 2019-04-25
US20200246267A1 (en) 2020-08-06
ZA202001675B (en) 2021-07-28
MX2020003413A (en) 2020-07-20
TW201927288A (en) 2019-07-16
AU2018350846A1 (en) 2020-04-23
TW202146031A (en) 2021-12-16
IL273852A (en) 2020-05-31
BR112020007470A2 (en) 2020-10-27
EP3858333A1 (en) 2021-08-04
US20210161818A1 (en) 2021-06-03
JP2021500324A (en) 2021-01-07
CN111246845A (en) 2020-06-05

Similar Documents

Publication Publication Date Title
IL273852A (en) Preparation and storage of liposomal rna formulations suitable for therapy
EP3621648A4 (en) Msln targeting trispecific proteins and methods of use
IL259100A (en) Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
ZA201807519B (en) Liposomal preparation and methods of treatment
ZA202001487B (en) Liposomal formulations comprising saponin and methods of use
IL261996A (en) Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
IL253796A0 (en) Therapeutically active compounds and their methods of use
EP3416671A4 (en) Nucleic acid carriers and therapeutic methods of use
EP3749344A4 (en) Methods for therapeutic use of exosomes and y-rnas
ZA202106237B (en) Preparation and storage of liposomal rna formulations suitable for therapy
IL266198A (en) Liposomal formulation for use in the treatment of cancer
EP3694832A4 (en) Extended release pharmaceutical formulation and methods of treatment
EP3380525A4 (en) Pharmaceutical formulations and methods of use thereof
EP3526205A4 (en) Therapeutic compounds and methods of use thereof
EP3416691A4 (en) Nucleic acid carriers and therapeutic methods of use
IL261655B (en) Liposomal formulations and methods of using same in agriculture
EP3290034A4 (en) Use of trimethazine in preparation of drugs for preventing and treating liver diseases
RS63154B1 (en) Immunoconjugates targeting adam9 and methods of use thereof
EP3463366A4 (en) Topical formulations of pde-4 inhibitors and their methods of use
IL266132A (en) Pharmaceutical formulations and methods of making the same
IL280000A (en) Tumor reduction formulations and methods of use thereof
EP3313520A4 (en) Therapeutic uses of berberine formulations
EP3313427A4 (en) Therapeutic peptides and methods of use thereof
EP3497243A4 (en) Cell therapy compositions and methods of use thereof
EP3346989A4 (en) Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer